Clifford Siporin, the president of Greystone Pharmaceutical Consultants, a contract research organization (CRO) in Parkland, Fla., has a challenge.

Looking to cure a host of neurodegenerative diseases, StemCells, a Palo Alto, Calif.-based company, has transplanted human neural stem cells into the brains of thousands of mice.

When Human Genome Sciences in Rockville, Md., recruits top scientists, the biotechnology company usually offers them a stake in its future success in the form of stock options.

Infections of three lab workers with tularemia at BSL-2 lab puts plan in spotlight again

Industry believes that tax reform will boost innovation, but some scientists are unsure

Much like an uncertain weather forecast predicting sun and patchy clouds, industry analysts see mixed prospects for European biotechnology companies in 2005.

Landmark suit by nuclear test veterans hinges on scientific evidence of cancer link

Two leading members of France's largest biotech trade organization, France Biotech, say the country's recent decision to allow human embryonic stem cell research moves the industry forward, but not far or fast enough to catch up with the United States and Great Britain.Alain Guedon, vice president of Paris-based France Biotech, says moral and ethical concerns will continue to hamper research despite the new law. His organization represents about 150 biotech companies. "France is pretending to be

Drastic changes to French fiscal regime in bid to encourage technology companies.

Volume 16 | Issue 13 | 42 | Jun. 24, 2002 Previous | Next Scientists Parlay Youth into Top French Jobs Sluggish reform in France's rigid tenure systems assuages some young researchers | By Clare Kittredge Image: Getty Images Dana Philpott enjoys rare success among scientists in their thirties in France. Many French postdoctoral trainees leave the country to do research and return home only to